First ACS cancer report highlights neoadjuvant therapy expansion, improvements
Editor's Note A significant increase in the use of neoadjuvant systemic cancer therapies is among the most notable findings from the first annual cancer report from The American College of Surgeons (ACS) National Cancer Database (NCDB). The report also emphasizes the value of early detection, innovative therapies, and robust datasets…
Study: Active monitoring without surgery safe for certain low-risk DCIS patients
Editor's Note Active monitoring for certain breast cancer patients offers similar outcomes to surgery with fewer side effects, according to research detailed in a December 16 article from Oncology News Central. Presented at the 2024 San Antonio Breast Cancer Symposium and published in JAMA, The COMET trial supports the safety…
Data support option to skip sentinel lymph node biopsy in early breast cancer
Editor's Note Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative early breast cancer provides noninferior outcomes compared to undergoing the procedure, MedPage Today reported December 13. Presented at the San Antonio Breast Cancer Symposium and published in the New England Journal of Medicine, the INSEMA trial found…
Q&A: Perioperative immunotherapy advances for early-stage NSCLC
Editor's Note Perioperative immunotherapy is reshaping treatment strategies for early-stage non-small cell lung cancer (NSCLC) without actionable mutations, according to Dr. Roy S. Herbst of Yale Cancer Center. In a recent interview with OncLive, the oncology expert highlighted the promise of neoadjuvant and adjuvant therapies to improve outcomes for these…
Study: COVID-19's impact on oncological surgery offers lessons for future crises
Editor's Note A scoping review of 15 studies reveals that the COVID-19 pandemic significantly disrupted oncological abdominal surgery (OAS), leading to postponed or canceled procedures, adoption of alternative treatment plans, and increased psychological stress among surgical teams. Published November 5 in the American Journal of Surgery, the findings emphasize the…
Study: Stool tests show promise in reducing colonoscopies for post-polypectomy colorectal cancer surveillance
Editor's Note Stool-based testing strategies could significantly reduce the number of colonoscopies required for post-polypectomy colorectal cancer (CRC) surveillance while maintaining equivalent long-term outcomes in cancer incidence and mortality, according to research published August 30 in Gastroenterology. Conducted in the Netherlands, the cross-sectional observational study compared three stool tests—multitarget stool…
Study: Wearable devices improve postoperative physical activity in lung cancer patients
Editor's Note In a recent study, lung cancer patients using wearable devices showed significantly improved postoperative physical activity and pulmonary function as well as reduced symptoms such as dyspnea and pain. Published September 20 in Jama Network Open, the study compared 74 patients in the intervention group (who used wearable…
Algorithm enhances decision-making on intermediate-stage liver cancer surgery, treatment
Editor's Note An algorithm developed by researchers at Duke University Medical Centre is designed to assist patients diagnosed with intermediate-stage liver cancer in making decisions about surgery, according to an October 9 report in News Medical Life Sciences. Known as the Modified Metroticket, this tool predicts overall survival and recurrence-free…
Immunotherapy’s FDA approval expected to improve lung cancer treatment
Editor's Note The US Food & Drug Administration (FDA) has approved immunotherapy durvalumab for perioperative treatment of resectable non-small cell lung cancer (NSCLC), according to an August 15 announcement. The approval is for durvalumab (Imfinzi, AstraZeneca) in combination with platinum-based chemotherapy as a neoadjuvant treatment, followed by durvalumab alone as…
Study: Starting adjuvant chemotherapy more than 6 weeks after surgery worsens colorectal cancer survival
Editor's Note A post hoc analysis of the SCOT phase 3 randomized clinical trial reveals that initiating adjuvant chemotherapy more than 6 weeks after surgery is linked to worse disease-free survival (DFS) in patients with high-risk stage II and stage III colorectal cancer. Published June 12 in JAMA Surgery, the…
Free Daily News
- Novel noninvasive surgical approach shows promise in treating severe OCD
- Study: Preop mental health assessment improves postop outcomes for older patients
- Study: Adenotonsillectomy reduces healthcare use in children with mild sleep-disordered breathing
- Introducing New Leader Toolkit: Your guide to OR leadership success
- Northwestern tests autonomous blood draw robot
- Unplanned hospital admissions post ASC visits remain exceptionally low, study finds
- Cardiology efficiency, orthopedic revenue surge as ASCs navigate growing complexity
- Study: BMI, hidden tumors complicate intubation
- New 7T MRI technique pinpoints hidden epilepsy-causing brain lesions
- Wildfires linked to longer postop hospital stay following lung cancer surgery, study finds